Protecting platelets.
Defending patients.

Tavlesse®, the first spleen tyrosine kinase inhibitor indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments1,2

Stand strong against platelet destruction.

Provide your patients with an opportunity for a lasting defence3

Tavlesse is the 1st and only targeted agent that helps prevent immune-mediated platelet destruction.4

Early onset of efficacy and robust improvements in platelet levels4

Median time to first response was 15 days in overall responders4

59% less bleeding vs placebo1, 2, 5

No serious or severe bleeding5

Less rescue medication required vs placebo4

59% did not require rescue medication at any visit5

Durable benefit5

Demonstrated improvements in platelet counts for up to 4 years5

Oral dosing with no food restrictions1,2

The convenience of an oral medication that can be taken with or without food1,2

Mild to moderate adverse reactions1,2

The majority of adverse reactions observed in clinical trials were mild or moderate. However, serious adverse reactions such as febrile neutropenia, hypertensive crisis or infections may occur4

Learn about Chronic ITP

ITP is a heterogeneous disease with a complex, multifactorial pathogenesis6

Tavlesse in Chronic ITP

Tavlesse is indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments1,2

Want to know more about Tavlesse?
Sign up to our mailing list

Indiction: Tavlesse is indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments.
ITP: immune thrombocytopenia

References:

  1. Tavlesse Summary of Product Characteristics. Great Britain. Grifols. Date of revision: January 2021. Available at https://www.medicines.org.uk/emc/product/11479. Accessed on 14/2/2022.
  2. Tavlesse Summary of Product Characteristics. Northern Ireland. Grifols. Date of revision: August 2021. Available at https://www.emcmedicines.com/en-gb/northernireland/medicine?id=9c2f7cf0-129d-42a3-a61c-d729ae80e50c. Accessed on 14/2/2022.
  3. Bussel J, Arnold DM, Boxer MA, et al. Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial programme. Am J Hematol. 2019;94(5):546-553
  4. Bussel J, et al. Am J Hematol. 2018;93:921–930. Doi:10.1002/ajh.25125
  5. Data on file. Grifols
  6. Cine DB, Bussel J, Liebman HA, et al. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009; 113(26):6511-6521